 |
|
|
| |
Evaluation of the drug-drug interaction profile of vebicorvir,
a first-generation hepatitis B core inhibitor: findings from
Phase 1 and Phase 2a studies
|
| |
| |
EASL: Deeper virologic suppression with the addition of vebicorvir, a first-generation hepatitis B core inhibitor, to entecavir correlates with reduced inflammation and fibrosis-4 index in treatment-naïve patients with HBeAg positive chronic hepatitis B - (06/26/22)
EASL: ABI-4334, a novel inhibitor of hepatitis B virus core protein, promotes formation of empty capsids and prevents cccDNA formation by disruption of incoming capsids - (06/30/22)
EASL: Improving the pharmacokinetic profile of the hepatitis B virus core inhibitor ABI-H3733 following oral administration: results from new formulation activities - (06/26/22)
EASL 2022 June 22-26 London
Katie Zomorodi, Grace Wang, Steven J Knox, Julie Ma, Luisa M Stamm
Assembly Biosciences, Inc., South San Francisco, CA, USA
|
| |
|
|
|
|
|
